Patients
17.6 % of people
People aged 65 and over, New Zealand, 2025 (World Bank).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
New Zealand NAD+ Supplements Market Industry Trends and Forecast to 2034: Segmented by (Ingredient, Form, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $4.8 Mn | — | — |
| 2025 (base) | $5.3 Mn | +$0.5 Mn | — |
| 2026 (forecast) | $5.9 Mn | +$0.6 Mn | +11.2% |
| 2027 (forecast) | $6.6 Mn | +$0.7 Mn | +23.7% |
| 2028 (forecast) | $7.3 Mn | +$0.7 Mn | +37.5% |
| 2029 (forecast) | $8.1 Mn | +$0.8 Mn | +52.9% |
| 2030 (forecast) | $9.0 Mn | +$0.9 Mn | +70% |
| 2031 (forecast) | $10.1 Mn | +$1.0 Mn | +89.1% |
| 2032 (forecast) | $11.2 Mn | +$1.1 Mn | +110.2% |
| 2033 (forecast) | $12.4 Mn | +$1.3 Mn | +133.8% |
| 2034 (forecast) | $13.8 Mn | +$1.4 Mn | +160% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $5.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $13.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Nicotinamide Adenine Dinucleotide (NAD+) Supplements |
| Segments | Ingredient, form and distribution channel (see all) |
| Key players | ChromaDex, Elysium Health, Thorne, Life Extension, Renue By Science (see all) |
| Regulator in New Zealand | Medsafe and MPISource: Medsafe. Checked 14 Nov 2026.Source: Ministry for Primary Industries. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
NAD+ supplements, such as NMN and nicotinamide riboside, aim to raise levels of NAD+, a molecule linked to cell energy that falls with age.
Key segments of the NAD+ Supplements market include ingredient (Nicotinamide Riboside, NMN and NAD+ Direct) and form (Capsules, Powders and IV and Injections).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the NAD+ Supplements market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the NAD+ Supplements market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the NAD+ Supplements market.
The NAD+ Supplements market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Dietary supplements are regulated as food, under the Ministry for Primary Industries (MPI).[2] People aged 65 and over: 17.6% of people in 2025, the latest World Bank figure for New Zealand.[3]
[1] Medsafe. Checked 14 Nov 2026.
[2] Ministry for Primary Industries. Checked 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.
Food and supplement rules, labelling and health-claim regulations govern NAD+ Supplements products. Authorities such as the US FDA, EFSA and national food safety bodies set what can be sold and claimed in New Zealand.
What doctors and scientists are doing in NAD+ Supplements right now, from free public sources.
17.6 % of people
People aged 65 and over, New Zealand, 2025 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.
From our blog
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
Healthcare Services · New Zealand
Digital Health · New Zealand
Pharmaceuticals · New Zealand
Medical Devices · New Zealand
Medical Devices · New Zealand
Medical Devices · New Zealand